Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Publications: Neisseria meningitidis

2000 to Present:

  • Centers for Disease Control and Prevention. Comparison of Meningococcal Disease Surveillance Systems – United States, 2005-2008. MMWR. 2012;61(17):306-08.
  • Krauland MG, Dunning Hotopp JC, Riley DR, Daugherty SC, Marsh JW, Messonnier NE, Mayer LW, Tettelin H, Harrison LH. Whole genome sequencing to investigate the emergence of clonal complex 23 Neisseria meningitidis serogroup Y disease in the United States. PLoS One. 2012; 7(4): e35699.
  • Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR 2011;60(40):1391-2.
  • Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines – Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2011;60(3):72-6.
  • MacNeil JR, Cohn AC, Zell ER, Schmink S, Miller E, Clark T, et al. for the Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners. Early Estimate of the Effectiveness of Quadrivalent Meningococcal Conjugate Vaccine. Pediatr Infect Dis J. 2011; 30(6):451-5.
  • Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, et al. Prevalence and Genetic Diversity of Candidate Vaccine Antigens Among Invasive Neisseria meningitidis Isolates in the United States. Vaccine. 2011;29(29-30):4739-44.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2010.
  • Cohn AC, MacNeil JR, Harrison LH, Theodore J, Schmidt M, Pondo T, et al. Changes in Neisseria meningitidis Disease Epidemiology in the United States, 1998-2007: Implications for Prevention of Meningococcal Disease. Clin Infect Dis. 2010; 50(2):184-91.
  • Harrison LH, Shutt KA, Schmink SE, Marsh JW, Harcourt BH, Wang X, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era, United States, 2000-2005. J Infect Dis. 2010; 201(8):1208-24.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2009.
  • Wu HM, Harcourt BH, Wei S, Hatcher CP, Novak RT, Wang, X, et al. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med. 2009;360:886-892.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2008.
  • Centers for Disease Control and Prevention. Report from ACIP: Decision Not to Recommend Routine Vaccination of All Children Aged 2-10 Years with MCV4. MMWR. 2008;57(17);462-5.
  • Harrison LH, Kreiner CJ, Shutt KA, O’Leary M, Messonnier NER, Stefonek KR, et al. Risk factors for meningococcal disease in students in grades 9-12. Ped Infect Dis J. 2008;27:193-199.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2007.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2006.
  • Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, et al. Neisseria meningitidis group B correlates of protection and assay standardization - International Meeting Report, Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006;24:5093-107.
  • Harrison LH, Jolley KA, Shutt KA, Marsh JW, O'Leary M, Thomson Sanza L, et al. Antigenic shift and the incidence of meningococcal infection. J Infect Dis. 2006;193(9):1266-74.
  • Harrison LH, Maiden MC. Reply to Tsang et al. J Infect Dis. 2006;194:1792-3.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2005.
  • Centers for Disease Control and Prevention. Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005;54(RR-7):1-21.
  • Dull P, Abdelwahab J, Sacchi C, Becker M, Noble C, Kaiser R, et al. Serogroup W-135 Neisseria meningitidis carriage among U.S. travelers to the 2001 Hajj. J Infect Dis. 2005;191:33-9.
  • Rainbow J, Cebelinski E, Bartkus J, Glennen A, Boxrud D, Lynfield R. Rifampin-resistant meningococcal disease. Emerg Infect Dis. 2005;11(6):977-9.
  • Sejvar JJ, Johnson D, Popovic T, Miller JM, Downes F, Somsel P, et al. Assessing the risk of laboratory-acquired meningococcal disease in the United States, 1996-2000. J Clin Microbiol. 2005;24:4811-4.
  • Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics. 2005;115(5):1220-32.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2004.
  • McEllistrem MC, Kolano JA, Pass MA, Caugant DA, Mendelsohn A, Pacheco AGF, et al. Epidemiologic trends and genotypes causing meningococcal disease, Maryland. Emerg Infect Dis. 2004;10:451-6.
  • Mothershed EA, Sacchi CT, Whitney AM, Barnett GA, Ajello GW, Schmink S, et al. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol. 2004; 42:320-8.
  • Raghunathan PL, Bernhardt SA, Rosenstein NE. Opportunities for control of meningococcal disease in the United States. Ann Rev Med. 2004;55:333-53.
  • Zimmer S, Stephens DS. Meningococcal conjugate vaccine. Expert Opin Pharmacother. 2004;4:855-63.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2003.
  • Dolan-Livengood JM, Miller YK, Kahler CM, Reeves M, Ajello G, Stephens DS. Genetic basis for nongroublable Neisseria meningitidis. J Jnfect Dis. 2003;187:1616-28.
  • Shepard CW, Rosenstein NE, Fischer M, and the Active Bacterial Core Surveillance Team. Neonatal meningococcal disease in the United States, 1990-1999. Pediatr Infect Dis J. 2003;22:418-22.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2002.
  • Kellerman S, McCombs K, Ray M, Farley MM, Rosenstein N, Popovic T, et al. Genotype-specific carriage of Neisseria meningitidis in Georgia counties with hyper- and hyposporadic rates of meningococcal disease. J Infect Dis. 2002;186:40-8.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2001.
  • Finn R, Groves C, Coe M, Pass M, Harrison LH. A cluster of serogroup C meningococcal disease associated with attendance at a party. South Med J 2001;94(12):1192-4.
  • Harrison LH, Pass MA, Mendelsohn AB, Egri M, Pass M, Rosenstein NE, et al. Invasive meningococcal disease in adolescents and young adults. JAMA 2001;286:694-9.
  • Lingappa JR, Rosenstein N, Zell ER, Shutt KA, Schuchat A, Perkins BA and the Active Bacterial Core Surveillance (ABCs) Team. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine. 2001;19(31):4566-75.
  • Popovic T, Schmink S, Rosenstein NA, Ajello GW, Reeves MW, Plikaytis B, et al. Evaluation of pulsed-field gel electrophoresis in epidemiological investigations of meningococcal disease outbreaks caused by Neisseria meningitidis serogroup C. J Clin Microbiol. 2001;39(1):75-85.
  • Rosenstein NE , Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001;344:1378-88.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2000.
  • Rosenstein NE, Stocker SA, Popovic T, Tenover FC, Perkins BA, and the Active Bacterial Core Surveillance Team. Antimicrobial resistance of Neisseria meningitidis in the United States, 1997. Clin Infect Dis. 2000;30:212-3.
  • Sacchi CT, Whitney AM, Popovic T, Beall DS, Reeves MW, Plikaytis BD, et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis. 2000;182:1169-76.
  • Tondella M, Popovic T, Rosenstein N, Lake D, Carlone G, Perkins B. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. J Clin Microbiol. 2000;38:3323-8.

Top of Page

1995-1999:

  • Centers for Disease Control and Prevention. 1999. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 1999.
  • Diermayer M, Hedberg K, Hoesly F, Fischer M, Perkins B, Reeves M, et al. Epidemic serogroup B meningococcal disease in Oregon : the evolving epidemiology of the ET-5 strain. JAMA. 1999;281(16):1493-7.
  • Harrison LH, Dwyer DM, Maples CT, Billmann L. The risk of meningococcal infection in college students. JAMA. 1999;281:1906-10.
  • Rosenstein NE, Perkins BA, Stephens D, Lefkowitz L, Cartter ML, Danila R, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999;180:1894-1901.
  • Yusuf HR, Rochat RW, Baughman WS, Gargiullo PM, Perkins BA, Brantley MD, et al. Maternal cigarette smoking and invasive meningococcal disease: a cohort study among young children in metropolitan Atlanta, 1989-1996. Am J Public Health 1999;89:712-7.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 1998.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 1997.
  • Centers for Disease Control and Prevention. Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1997;46(No. RR-5):1-10.
  • Centers for Disease Control and Prevention. Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1997;46(No. RR-5):13-21.
  • Fischer M, Hedberg K, Cardosi P, Plikaytis BD, Hoesly FC, Steingart KR, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J. 1997;16:979-83.
  • Raymond NJ, Reeves M, Ajello G, Baughman W, Gheesling LL, Carlone GM, et al. Molecular epidemiology of sporadic (endemic) serogroup C meningococcal disease. J Infect Dis. 1997;176:1277-84.
  • Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci. 1997; 94:271-6.
  • Zangwill K, Schuchat A, Riedo FX, Pinner RW, Koo DT, Reeves MW, et al. School-based clusters of meningococcal disease in the United States: descriptive epidemiology and a case-control analysis. JAMA. 1997;277:389-95.
  • Centers for Disease Control and Prevention. Serogroup Y meningococcal disease -- Illinois, Connecticut, and selected areas, United States, 1989-1996. MMWR 1996;45:1010-13.
  • Centers for Disease Control and Prevention. Serogroup B Meningococcal Disease -- Oregon 1994. MMWR. 1995;44:121-4.
  • Jackson LA, Schuchat A, Gorsky RD, Wenger JD. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. Am J Public Health. 1995;85:843-5.
  • Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States : An emerging threat. JAMA. 1995;273:383-9.
  • Reeves MW, Perkins BA, Diermayer M, Wenger JD. Epidemic-associated Neisseria meningitidis detected by multilocus enzyme electrophoresis. Emerg Infect Dis. 1995;1:53-4.
  • Stephens DS, Hajjeh RA, Baughman WS, Harvey CH, Wenger JD, Farley MM. Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann Intern Med. 1995;123:937-40.

Top of Page

1988 - 1994:

  • Jackson LA, Tenover FC, Baker C, Plikaytis BD, Reeves MW, Stocker SA, et al. Prevalence of Neisseria meningitidis relatively resistant to penicillin in the United States, 1991. J Infect Dis. 1994;169:338-41.
  • Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected counties, United States, 1989-1991. MMWR. 1993;42:21-30.
  • Pinner RW, Gellin BG, Bibb WF, Baker CN, Weaver R, Hunter SB, et al. Meningococcal disease in the United States - 1986. J Infect Dis. 1991;164:368-74.

Top of Page

 

Images and logos on this website which are trademarked/copyrighted or used with permission of the trademark/copyright or logo holder are not in the public domain. These images and logos have been licensed for or used with permission in the materials provided on this website. The materials in the form presented on this website may be used without seeking further permission. Any other use of trademarked/copyrighted images or logos requires permission from the trademark/copyright holder...more

External Web Site Policy This graphic notice means that you are leaving an HHS Web site. For more information, please see the Exit Notification and Disclaimer policy.

 
Contact Us:
  • Centers for Disease Control and Prevention
    1600 Clifton Rd
    Atlanta, GA 30333
  • 800-CDC-INFO
    (800-232-4636)
    TTY: (888) 232-6348
    Contact CDC-INFO
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #